Report Overview

Germany Hepatitis C Testing Market - Industry Trends & Forecast Report 2028

Germany's Hepatitis C Testing Market was worth USD 82.7 million in 2021 and is projected to reach USD 135.7 million by 2028, exhibiting a CAGR of 7.9% in the forecast period. The rapid expansion of the market is predominantly due to the prevalence of hepatitis C among the population in Germany, coupled with the rising initiatives taken by the government to eliminate the occurrences of Hepatitis C in the country. Moreover, the rising influx of migrants in the country is expected to increase the incidence of HCV infections, propelling the Germany Hepatitis C Testing market demand.

Germany Hepatitis C Testing Market - Overview

The hepatitis C virus causes the liver infection known as hepatitis C (HCV). Hepatitis C spreads via. contact with an infected person's blood by sharing needles or other equipment used to prepare and inject drugs. Hepatitis C is not preventable by vaccination, the two serious adverse effects of chronic hepatitis C are cirrhosis and liver cancer. Avoiding practises that can transmit the disease, including drug injection and getting tested for hepatitis, is the greatest method to prevent hepatitis C. To determine if a person has ever had hepatitis C, a blood test known as an HCV antibody test is utilized. CDC (Centers for Disease Control and Prevention) now recommends one-time hepatitis C testing of all adults (18 years and older), all pregnant women during every pregnancy, and people who inject drugs, be tested regularly.

Germany Hepatitis C Testing Market Forecast and Trends

Growth Drivers

Prevalence of hepatitis C amongst the masses in the country

The rising prevalence of hepatitis C among the masses in Germany is set to contribute to the growth of the testing market. The need for hepatitis C testing kits in Germany would increase as the number of drug addicts increased. Sharing needles or other injecting equipment is the most common way for people to contract the hepatitis C virus. Besides, the growing influx of migrants in the country is expected to increase the incidence of HCV infections, which is another factor that would augment Germany's hepatitis C testing market growth in the upcoming years. Chronic hepatitis C can leads to serious health problems like cirrhosis and liver cancer. The high incidence rate of chronic infection with hepatitis C virus and sharing needles are causing the hepatitis C testing market to soar across the country.

Rising initiatives are taken by the government coupled with the German healthcare system in the country

The WHO's strategy is aligned with the HCV elimination strategy in Germany (BIS 2030), an integrated strategy for HIV, hepatitis B, C, and other STDs. By preventing illnesses like AIDS, liver cirrhosis, and HCC, this method hopes to enhance the health of the German populace. In Germany, there are two types of health insurance: statutory and private. Patients are not involved in the financial decision-making process, and copayment is kept to a minimum in statutory health. A contract between the sick fund and service providers exists in statutory health. Under statutory health insurance, HCV testing and treatment are covered. All citizens of Germany have access to the healthcare system through statutory health insurance and the choice to opt out of private health insurance. The aforementioned government initiative expected to contribute in market growth of hepatitis C testing at a faster pace in upcoming years.

Rising healthcare awareness in the population regarding the hepatitis C

The promotion of government and non-government organizations in rising awareness and growing demand for POC diagnostics are the primary drivers for market growth. For instance, a sizable portion of people with HCV infection goes on to develop the chronic form of the illness. Individuals who have ongoing hepatitis C are more likely to get other illnesses like liver cancer and liver failure. A sizeable fraction of the population is anticipated to choose HCV testing as public awareness of early treatment with quickly acting antivirals grows. Hence, robust investment in creating a comprehensive Hepatitis C testing initiative will present ample growth opportunities for the hepatitis C testing market to grow in the forecast period of 2022 to 2028.

Restraints

The Lack Of A Widespread Testing Program May Hinder Growth.

The lack of a widespread testing program is one of the most important barriers preventing the widespread adoption of hepatitis C testing in Germany. Hepatitis C testing has been adopted nationwide despite a rise in the disease frequency due to the lack of a comprehensive HCV testing strategy. According to numerous clinical articles, there is a clear need in Germany for a national hepatitis C testing strategy. Furthermore, it is projected that Germany won't be able to achieve the WHO objective of eliminating HCV by 2030 due to the lack of widespread testing. During the forecast period, these factors are projected to restrain the growth of the German hepatitis C testing market.

Impact of COVID-19 on Germany Hepatitis C Testing Market

Due to fewer hospital visits caused by the COVID-19 outbreak, the market for hepatitis testing suffered. As a result of pandemic healthcare systems are under a lot of stress. To reduce the disease's spread and save resources for COVID-19 sufferers, healthcare institutions and clinicians were told to avoid performing elective surgical procedures and physical exams. As a result, this nation's number of tests performed in many clinical laboratories for hepatitis dropped quickly. Furthermore, the management of coronavirus transmission greatly used the growing resources needed for hepatitis C testing.

Germany Hepatitis C Testing Market - By Test Type

Based on test types, the Germany hepatitis C testing market is divided into three categories, including HCV serologic tests (HCV Ab), HCV RNA tests, and HCV genotype testing. With the biggest market share for hepatitis C testing in Germany, the HCV serologic tests (HCV Ab) segment is predicted to lead the market in upcoming years. Hepatitis C testing demand in Germany is projected to increase due to the urgent need to screen the vulnerable and general population for HCV antibodies. This blood test detects the body's antibodies to fight the virus. When the body detects the hepatitis C virus in the blood, it produces these proteins. Besides during the forecast period, the HCV RNA and HCV genotype expected to grow at a significant rate.

Germany Hepatitis C Testing Market - By Technology

Based on technology the hepatitis C testing market is segmented into enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). The ELISA technology dominated the market for hepatitis C testing. The substantial proportion of the hepatitis C testing market is primarily due to the widespread use of ELISA tests to identify hepatitis in clinical settings. After ELISA, PCR is the second most dominating segment for hepatitis C testing. PCR is used for both HCV RNA testing and HCV genotype testing. With the widespread use and awareness of PCR the market segment anticipated to propel in upcoming years at a faster pace.

Competitive Landscape

Key players operating in Germany Hepatitis C Testing Market are Abbott, Roche Diagnostics, Siemens Healthcare, Bio-Rad Laboratories, DiaSorin S.P.A, AbbVie, GlaxoSmithKline, Ever Pharma, Alpen Pharma Group, Amgen, and Other Prominent Players. The Germany Hepatitis C Testing Market is slightly fragmented with the presence of few established and emerging companies in the country. To broaden their presence, the market leaders are striving to meet the WHO's guidelines for eliminating hepatitis C. Other strategies are used, such as strategic alliances, contracts, mergers, and partnerships.

Recent Development

• In January 2021, The World Health Organization (WHO) updated its guidelines Development Group (GDG) membership list, creating guidelines for hepatitis C self-testing.

Scope of the Report

By Test Type

• HCV Serologic Tests
• HCV RNA Tests
• HCV Genotype

By Technology

• ELISA
• PCR

By End-User

• Hospitals
• Diagnostics
• Others

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. Germany Hepatitis C Testing Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Landscape/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. Germany Hepatitis C Testing Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test Type
         1. HCV Serologic Tests
         2. HCV RNA Tests
         3. HCV Genotype
      2. By Technology
         1. ELISA
         2. PCR
      3. By End-User
         1. Hospitals
         2. Diagnostics
         3. Others
5. Competitive Landscape
   1. List of Key Players and Their Offerings
   2. Market Share Analysis, 2021
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
6. Impact of Covid-19 on Germany Hepatitis C Testing Market
7. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
   1. Abbott
   2. Roche Diagnostics
   3. Siemens Healthcare
   4. Bio-Rad Laboratories
   5. DiaSorin S.P.A
   6. AbbVie
   7. GlaxoSmithKline
   8. Ever Pharma
   9. Alpen Pharma Group
   10. Amgen
   11. Other Prominent Players
8. Key Strategic Recommendations
9. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation

Note: Financial in information in case of non-listed companies will be provided as per availability

The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

Figure 1        Germany Hepatitis C Testing Market Segmentation

Figure 2        Germany Hepatitis C Testing Market Value Chain Analysis

Figure 3        Company Market Share Analysis, 2021

Figure 4        Germany Hepatitis C Testing Market Size, By Value (USD Million), 2018-2028

Figure 5        Germany Hepatitis C Testing Market Share, By Test Type, By Value, 2018-2028

Figure 6        Germany Hepatitis C Testing Market Share, By Technology, By Value, 2018-2028

Figure 7        Germany Hepatitis C Testing Market Share, By End-User, By Value, 2018-2028

List of Tables

Table 1         Germany Hepatitis C Testing Market Size, By Test Type, By Value, 2018-2028          

Table 2         Germany Hepatitis C Testing Market Size, By Technology, By Value, 2018-2028        

Table 3         Germany Hepatitis C Testing Market Size, By End-User, By Value, 2018-2028 

Table 4         Abbott Company Overview                              

Table 5         Abbott Financial Overview                               

Table 6         Roche Diagnostics Company Overview                                  

Table 7         Roche Diagnostics Technology Overview                                

Table 8         Siemens Healthcare Company Overview                                

Table 9         Siemens Healthcare Financial Overview                                 

Table 10        Bio-Rad Laboratories Company Overview                              

Table 11        Bio-Rad Laboratories Financial Overview                               

Table 12        DiaSorin S.P.A Company Overview                             

Table 13        DiaSorin S.P.A Financial Overview

Table 14        AbbVie Company Overview                              

Table 15        AbbVie Financial Overview                               

Table 16        GlaxoSmithKline Company Overview                                    

Table 17        GlaxoSmithKline Financial Overview                                     

Table 18        Ever Pharma Company Overview                                

Table 19        Ever Pharma Financial Overview

Table 20        Alphen Pharma Group Company Overview                             

Table 21        Alphen Pharma Group Financial Overview 

Table 20        Amgen Company Overview                              

Table 21        Amgen Financial Overview